In a regulatory filing, Kymera Therapeutics disclosed that its director Bruce Booth sold 454K shares of common stock on July 9th in a total transaction size of $17.3M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
- Kymera Therapeutics Advances with Sanofi in Phase 2 Trials
- Kymera expands HS and AD Phase 2 trials following review
- Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
- Kymera Therapeutics Shareholders Approve Key Governance Proposals